A61K 31/196
The amino group being directly attached to a ring
Official title: the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
A61K31/196 (The amino group being directly attached to a ring) appears on 1,548 US grants and 2,831 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,548
- Published applications
- 2,831
- Assignees
- 1,248
- Inventors
- 4,690
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1978 | 1 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 1 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 1 | 0 |
| 1995 | 3 | 0 |
| 1996 | 9 | 0 |
| 1997 | 16 | 0 |
| 1998 | 25 | 0 |
| 1999 | 43 | 0 |
| 2000 | 27 | 0 |
| 2001 | 26 | 8 |
| 2002 | 24 | 38 |
| 2003 | 24 | 53 |
| 2004 | 20 | 52 |
| 2005 | 11 | 58 |
| 2006 | 21 | 44 |
| 2007 | 26 | 49 |
| 2008 | 12 | 57 |
| 2009 | 7 | 95 |
| 2010 | 20 | 82 |
| 2011 | 21 | 83 |
| 2012 | 40 | 103 |
| 2013 | 55 | 139 |
| 2014 | 89 | 169 |
| 2015 | 86 | 189 |
| 2016 | 90 | 157 |
| 2017 | 108 | 167 |
| 2018 | 108 | 162 |
| 2019 | 116 | 168 |
| 2020 | 101 | 168 |
| 2021 | 102 | 160 |
| 2022 | 74 | 186 |
| 2023 | 71 | 136 |
| 2024 | 55 | 116 |
| 2025 | 60 | 108 |
| 2026 | 54 | 84 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Piperidine urea derivatives for cancer therapy15 Sep 2026US 12,734,164 B2NeuroPn Therapeutics, Inc.
- Progesterone formulation to trigger ovulation and provide luteal phase support15 Sep 2026US 12,734,179 B2Augusta University Research Institute, Inc.
- Use of membrane inhibitors to enhance vaccine development against enveloped viruses8 Sep 2026US 12,728,161 B2Cornell University
- Combination treatment for Netherton syndrome1 Sep 2026US 12,721,834 B2Quoin Pharmaceuticals, Inc.
- Treatment of CNS disorders with sleep disturbances25 Aug 2026US 12,714,683 B2University of Copenhagen
- Combination treatment for netherton syndrome8 Oct 2026US 2026/0306448 A1Quoin Pharmaceuticals, Inc.
- Prolyl hydroxylase domain-containing protein (phd) inhibitors, combinations and uses thereof8 Oct 2026US 2026/0306471 A1Insilico Medicine IP Limited
- Hexahydro[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine deuterated derivative, pharmaceutical composition thereof, preparation method therefor, and anti-influenza use thereof8 Oct 2026US 2026/0308174 A1Changsha Jingyi Pharmaceutical Technology Co., Ltd
- Therapeutic compounds1 Oct 2026US 2026/0297016 A1Regents of the University of Minnesota
- Ferroptosis inhibitors24 Sep 2026US 2026/0283988 A1Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
Most cited
By later US patents
- Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments210US 5,668,117 A1997
- Recombinant A2-specific TNFα specific antibodies174US 7,070,775 B2Centocor, Inc. · 2006
- Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses155US 8,709,385 B2Foamix Ltd. · 2014
- Method for enhancing outflow of aqueous humor in treatment of glaucoma151US 6,228,873 B1The Regents of the University of California · 2001
- Penetrating pharmaceutical foam145US 7,700,076 B2Foamix Ltd. · 2010